Liquid Biopsy Market 2020 Global Growth Insights, Trends, Size, Share And Forecast To 2022

Liquid Biopsy Market Research Report: Information by Biomarker Types (Circulating Tumor Cells (CTCs), Circulating Tumor DNA (CTDNA), Extracellular Vesicles (EVS) and other Biomarker (Circulating RNA and Proteins)), Application (Cancer Therapeutic Application, Reproductive Health and Other Therapeutic Application), Sample (Blood Sample, Urine Sample and other), End User (Hospitals and Laboratories, Academic and Research Centers and other End Users) and Region (North America, Europe, Asia-Pacific and Middle East & Africa) - Global Forecast to 2022

Market Insights:

Liquid biopsy overcomes these problems of tissue biopsy by using biomarkers present in samples such as blood, urine etc. and thus is a comparatively non-invasive technique. Liquid biopsy also provides greater information about the sample which is real time. The real time data can be used for monitoring and thereby determining the treatment for diseases such as cancer. The greater sensitivity of tissue biopsy coupled with the development of sophisticated detectors with extremely low detection rates have enabled the early detection of diseases which is the holy grail of cancer.

Biopsy involves extracting a sample of tissue and testing it for the presence of diseases especially cancer. Traditional tissue biopsy is a painful technique and also has a high rate of false results. Moreover the technique is costly, time consuming and not applicable for extracting samples such as those close to vital organs such as heart.

Segmentation:

Global Liquid Biopsy market has been segmented on the basis of biomarker type which comprises of circulating tumor cells (Ctcs), circulating tumor DNA (Ctdna), extracellular vesicles (Evs) and other biomarker. On the basis of application; market is segmented into cancer therapeutic application, reproductive health, and other therapeutic application. On the basis of sample; market is segmented into blood, urine and others. On the basis of end-users; market is segmented into hospitals and laboratories, academic and research centres and others.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/710

Major Players

• Guardant Health, Inc.,
• Trovagene, Inc.,
• RainDance Technologies, Inc.,
• Agena Bioscience Inc. Inc.,
• Admera Health,
• Biocept, Inc.,
• Circulogene Theranostics,
• Inivata Ltd.,
• SAGA Diagnostics AB,
• Exosome Diagnostics and others.

Drivers

The market drivers for the liquid biopsy market growth are rising rates of cancer, growing investment in research and development, collaborations between companies and public organizations, rise in geriatric population, rising expenditure on health etc. The factors which are inhibiting the growth of the market includes the prohibitive costs associated with liquid biopsy and the differential awareness and availability between developing and the developed world. However, not all cancer patients benefit from early detection as some cancer types such as brain cancer and prostate cancer may lie dormant for many years. Further liquid biopsy is not all non-invasive as can be seen in case of using spinal fluid as sample.

Also the technique is not applicable to all types of cancer as some cancers such as brain cancer and prostate cancer may lie dormant for many years, and thus are either undetectable or detected very late which robs liquid biopsy of its advantages. Further liquid biopsy is not all non-invasive as can be seen in case of using spinal fluid as sample.

Regional Analysis:

Depending on geographic region, Liquid biopsy market is segmented into four key regions: Americas, Europe, Asia Pacific, and Middle East & Africa. Globally developed countries led by North America is the largest market for Liquid biopsy. Europe is the second-largest market for liquid biopsy. The developing regions market such as Asia pacific region and Middle East & Africa however is rising much faster.

Key findings

• Circulating tumor cells (CTCs) segment dominates both in terms of market share as well as revenues, contributing approx. 55.48% of the revenue share of the liquid biopsy market.
• On the basis of the therapeutic application, the segment for Cancer will reflect the highest growth potential, with over 82.83% of the market share by revenues. However, the urine sample segment is anticipated to witness noticeable growth.
• The market for liquid biopsy is dominated by North America and Europe and this trend will continue. Asia-Pacific market is the fastest growing market and is expected to grow at a CAGR of 29.7% during forecasted period

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/liquid-biopsy-market-710